Donepezil Tablet
Product Images NDC 60687-303

20 FDA label images from American Health Packaging · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Donepezil (NDC 60687-303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

5 mg Donepezil HCl Tablet

5 mg Donepezil HCl Tablet
Donepezil 10 mg tablet, round and white, with imprint '1' on one side and '24' on the other. The tablet is an oral dosage form of Donepezil hydrochloride, labeled by American Health Packaging.*
FDA Label Image

10 mg Donepezil HCl Tablet

10 mg Donepezil HCl Tablet
Donepezil 10 mg oral tablet shown from both sides. One side is imprinted with the letter 'I', and the other side is imprinted with the number '21'. The tablet is round and light brown in color. Labeler is American Health Packaging.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Donepezil hydrochloride showing the molecular arrangement including methoxy groups, a piperidine ring, and a benzyl group, with the associated hydrochloride component.*
FDA Label Image

Figure 1 (Image 01)

Figure 1 (Image 01)
Line graph depicting ADAS-cog change from baseline over 30 weeks of drug treatment showing mean values with standard error. The graph compares Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups, illustrating clinical improvement and decline relative to baseline.*
FDA Label Image

Figure 2 (Image 02)

Figure 2 (Image 02)
A cumulative percentage line graph depicting patient response to Donepezil Hydrochloride at 5 mg/day and 10 mg/day doses compared to placebo. The X-axis shows change from baseline in ADAS-cog scores, and the Y-axis shows cumulative percentage of patients. The graph includes a small table summarizing percentages of patients achieving specific change values (-7, -4, 0) in each treatment group.*
FDA Label Image

Figure 3 (Image 03)

Figure 3 (Image 03)
A bar graph depicting the CIBIC-Plus Rating distribution by percentage of patients for Donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The categories on the x-axis range from Markedly Improved to Markedly Worse, with the y-axis showing percentage of patients. The 10 mg/day group shows the highest percentage in the No Change category compared to other groups.*
FDA Label Image

Figure 4 (Image 04)

Figure 4 (Image 04)
A line graph showing the ADAS-cog change from baseline (mean ± SE) over weeks of drug treatment up to 12 weeks. It compares Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo. The y-axis ranges from clinical improvement to clinical decline, with baseline marked at zero change. Both Donepezil doses show trends toward clinical improvement compared to placebo.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A cumulative percentage of patients graph comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The x-axis shows change from baseline, and the y-axis shows cumulative percentage of patients. The graph includes annotations for changes of 7 points, 4 points, and no change, along with a small data table summarizing patient percentages within treatment groups for different changes in ADAS cognitive scores.*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
A bar chart depicting the percentage of patients by CIBIC-plus rating categories for three groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo. The ratings range from Markedly Improved to Markedly Worse, showing relative patient outcomes across treatment and placebo groups.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
A line graph depicting SIB (Severe Impairment Battery) change from baseline mean (± SE) over 0, 3, and 6 months of drug treatment. The graph compares Donepezil Hydrochloride 10 mg/day and placebo groups, showing an upward trend for Donepezil indicative of clinical improvement, and a downward trend for placebo indicating clinical decline. The vertical axis ranges from -8 to 8, and the horizontal axis measures months of treatment.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
A cumulative percentage of patients graph comparing Donepezil Hydrochloride 10 mg/day and placebo groups, showing SIB (Severe Impairment Battery) change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The graph illustrates two curves, with Donepezil Hydrochloride showing a more favorable change distribution than placebo.*
FDA Label Image

Figure 9 (Image 05)

Figure 9 (Image 05)
A line graph showing ADCS-ADL change from baseline over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The y-axis ranges from clinical improvement to clinical decline, with the baseline marked at zero. Donepezil shows less decline over time compared to placebo, with data points at 0, 3, and 6 months including error bars for each group.*
FDA Label Image

Figure 10 (Image 06)

Figure 10 (Image 06)
A cumulative percentage of patients graph comparing Donepezil Hydrochloride 10 mg to placebo. The x-axis shows the ADCS-ADL change from baseline, ranging from 20 to -20, and the y-axis shows the cumulative percentage of patients from 0 to 100 percent. The graph has two lines: one for Donepezil Hydrochloride 10 mg represented by filled circles, and one for placebo represented by open squares, illustrating patient distribution based on ADCS-ADL changes.*
FDA Label Image

Figure 11 (Image 07)

Figure 11 (Image 07)
A line graph showing SIB (Severe Impairment Battery) change from baseline (LS mean ± SE) over 24 weeks of drug treatment with Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The graph plots weeks on the x-axis and SIB change on the y-axis, indicating clinical improvement above baseline and clinical decline below. Two lines compare the changes for 10 mg/day (black circles) and 23 mg/day (white diamonds), with error bars representing standard error.*
FDA Label Image

Figure 12 (Image 08)

Figure 12 (Image 08)
A cumulative distribution plot illustrating the percentage of patients versus SIB (Severe Impairment Battery) change from baseline for Donepezil Hydrochloride at 10 mg/day and 23 mg/day doses. The graph shows two overlapping curves, comparing patient responses between these two dosage groups.*
FDA Label Image

Figure 13 (Image 09)

Figure 13 (Image 09)
Bar chart comparing the percentage of patients by CIBIC-plus rating for two daily doses of Donepezil Hydrochloride: 10 mg/day and 23 mg/day. The ratings range from Markedly Improved to Markedly Worse, showing distribution of patient response across these categories for each dose.*
FDA Label Image

5 mg Donepezil Tablets Carton.jpg (5 mg Donepezil Tablets Carton)

5 mg Donepezil Tablets Carton.jpg (5 mg Donepezil Tablets Carton)
Label for Donepezil Hydrochloride tablets, USP, 5 mg strength. The label shows a package containing 100 tablets (10 x 10) and states the drug is for prescription use only. It includes storage instructions, protection advice, and distribution by American Health Packaging, Columbus, Ohio. The label also features a barcode and a QR code for prescribing information.*
FDA Label Image

5 mg Donepezil Tablet Blister.jpg (5 mg Donepezil Tablet Blister)

5 mg Donepezil Tablet Blister.jpg (5 mg Donepezil Tablet Blister)
Donepezil hydrochloride tablet labels for 5 mg strength by American Health Packaging. Each label includes the product name, dosage strength (5 mg), barcodes, lot number, and expiry date placeholders. The text confirms the tablet form and oral route.*
FDA Label Image

10 mg Donepezil Tablets Carton.jpg (10 mg Donepezil Tablets Carton)

10 mg Donepezil Tablets Carton.jpg (10 mg Donepezil Tablets Carton)
Donepezil Hydrochloride 10 mg Tablets, USP packaging label showing a 100-tablet count (10 x 10) in a blister pack. The label includes the NDC number 60687-303-01, states Rx Only, and provides storage, prescribing, and protection instructions. The labeler is American Health Packaging, with additional drug source information from Cambier Pharmaceuticals. A barcode and QR code for patient and prescribing information are also visible.*
FDA Label Image

10 mg Donepezil Tablet Blister.jpg (10 mg Donepezil Tablet Blister)

10 mg Donepezil Tablet Blister.jpg (10 mg Donepezil Tablet Blister)
Donepezil Hydrochloride Tablet, USP 10 mg label sheet showing multiple individual labels. Each label includes the product name, strength (10 mg), dosage form (tablet), barcode, a space for expiry date and lot number, and the labeler American Health Packaging, Columbus, Ohio.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.